Loading
A phase 3 trial of adebrelimab in lung cancer, run by Jinming Yu, not yet recruiting.
Adebrelimab Combined with Chemotherapy and Thoracic Radiotherapy for First-line Treatment of ES-SCLC is a phase 3, randomised interventional study registered as NCT06672133 by Jinming Yu, with a registry enrolment figure of 524 participants, started 2024-12 and due to reach its primary completion in 2029-06. Interventions recorded: Adebrelimab; Radiation Therapy. Conditions listed: Extensive Stage Lung Small Cell Carcinoma. Primary outcome: PFS; OS. Lung eligibility wording from the registry: "Histologically or cytologically confirmed extensive stage small cell lung cancer (according to the Veterans Lung Administration Lung Study Group, VALG stage);". No results are recorded here; the registry entry is the source.
Shares Adebrelimab, Extensive-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot), IMRT / IGRT (modern external beam) and the tag lung-deep-dive.
Shares Extensive-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot), IMRT / IGRT (modern external beam) and the tag lung-deep-dive.
Shares Adebrelimab, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Adebrelimab, Extensive-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot), IMRT / IGRT (modern external beam) and the tag lung-deep-dive.
Shares Adebrelimab, Extensive-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Adebrelimab, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Adebrelimab, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Extensive-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot), IMRT / IGRT (modern external beam) and the tag lung-deep-dive.